(9CI)-2-乙基八氢-吡咯并[1,2-a]吡嗪 | 88327-66-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: (9CI)-2-乙基八氢-吡咯并[1,2-a]吡嗪
• 英文名称: 4-ethyl-1,4-diazabicyclo<4.3.0>nonane
• 英文别名: 2-Ethyloctahydropyrrolo[1,2-a]pyrazine；2-ethyl-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazine
• CAS: 88327-66-6
• 化学式: C₉H₁₈N₂
• 分子量: 154.255
• InChiKey: SNALRIFMJPORKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为产物：
  描述：

  吡咯烷-2-甲胺 在 lithium aluminium tetrahydride 、 碳酸氢钠 作用下， 以 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 99.25h， 生成 (9CI)-2-乙基八氢-吡咯并[1,2-a]吡嗪
  参考文献：
  名称：

  Shukla, U. K.; Khanna, J. M.; Sharma, Satyavan, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1983, vol. 22, # 7, p. 664 - 668

  摘要：

  DOI：

文献信息

• DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF
  申请人：Tang Peng Cho

  公开号：US20120184543A1

  公开（公告）日：2012-07-19

  Dihydroperidinone derivatives, preparation process and pharmaceutical use thereof are disclosed. Specially, new dihydroperidinone derivatives represented by general formula (I), wherein each substituent of the general formula (I) is defined as in the description, their preparation process, pharmaceutical compositions comprising said derivatives and their use as therapeutical agents, especially as Plk kinase inhibitors are disclosed.

  二氢吡啶酮衍生物、其制备方法及药用途被揭示。特别是，根据通用式(I)表示的新二氢吡啶酮衍生物，其中通用式(I)的每个取代基如描述中所定义，它们的制备过程，包含所述衍生物的药物组合物以及它们作为治疗剂的用途，特别是作为Plk激酶抑制剂的用途被揭示。
• Substituted Sulfonamide Compounds
  申请人：Merla Beatrix

  公开号：US20090186899A1

  公开（公告）日：2009-07-23

  Substituted sulfonamide compounds corresponding to the formula I wherein m, n, p, Q, R 1 , R 2 , R 3 , R 4 , X, Y and Z have the respective meanings defined herein, pharmaceutical compositions containing such compounds, a process for their preparation, and the use of such compounds for the treatment and/or inhibition of pain and other conditions mediated by bradykinin receptor 1 (B1R) and/or bradykinin receptor 2 (B2R).

  对应于公式I的磺胺基替代化合物，其中m、n、p、Q、R1、R2、R3、R4、X、Y和Z具有在此定义的各自含义，包含这种化合物的药物组合物，其制备方法，以及利用这种化合物治疗和/或抑制由激肽激酶受体1（B1R）和/或激肽激酶受体2（B2R）介导的疼痛和其他病症。
• [EN] PYRAZOLE DERIVATIVES AND USES THEREOF AS INHIBITORS OF DLK<br/>[FR] DÉRIVÉS DE PYRAZOLE ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE DLK
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015091889A1

  公开（公告）日：2015-06-25

  The present invention provides for compounds of formula 0 and various embodiments thereof, and compositions comprising compounds of formula 0 and various embodiments thereof. In compounds of formula 0, the groups R1A, R1B, R1C, R1D, R2, R3, R4, R5 and R6 have the meaning as described herein. The present invention also provides for methods of using compounds of formula 0 and compositions comprising compounds of formula 0 as DLK inhibitors and for treating neurodegeneration diseases and disorders.

  本发明提供了公式0的化合物及其各种实施方式，以及包含公式0的化合物和其各种实施方式的组合物。在公式0的化合物中，基团R1A、R1B、R1C、R1D、R2、R3、R4、R5和R6的含义如本文所述。本发明还提供了使用公式0的化合物和包含公式0的化合物作为DLK抑制剂以及用于治疗神经退行性疾病和紊乱的方法。
• NOVEL AZABICYCLOHEXANES
  申请人：Jain Rajseh

  公开号：US20120165320A1

  公开（公告）日：2012-06-28

  The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.

  本发明涉及公式I的新化合物，其药学上可接受的衍生物，互变异构体，立体异构体包括R和S异构体，多晶型，前药，代谢物，盐或溶剂的形式。该发明还涉及用于合成公式I的新化合物，其药学上可接受的衍生物，互变异构体，立体异构体，多晶型，前药，代谢物，盐或溶剂的过程。
• Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor
  申请人：Chavez Frank

  公开号：US20080015200A1

  公开（公告）日：2008-01-17

  Benzofuro- and benzothienopyrimidine compounds are described, which are useful as H 4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H 4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.

  描述了苯并呋喃和苯并噻吩嘧啶化合物，这些化合物可用作H4受体调节剂。这类化合物可用于制备药物组合物，并用于治疗由H4受体活性介导的疾病状态、紊乱和病况，如过敏、哮喘、自身免疫疾病和瘙痒症。